Avadel Pharmaceuticals Statistics
Share Statistics
Avadel Pharmaceuticals has 96.36M shares outstanding. The number of shares has increased by 7.28% in one year.
| Shares Outstanding | 96.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 88.15M |
| Failed to Deliver (FTD) Shares | 145.91K |
| FTD / Avg. Volume | 10.4% |
Short Selling Information
The latest short interest is 11.53M, so 11.96% of the outstanding shares have been sold short.
| Short Interest | 11.53M |
| Short % of Shares Out | 11.96% |
| Short % of Float | 13.08% |
| Short Ratio (days to cover) | 7.55 |
Valuation Ratios
The PE ratio is -7.06 and the forward PE ratio is 19.34.
| PE Ratio | -7.06 |
| Forward PE | 19.34 |
| PS Ratio | 40.48 |
| Forward PS | 2.3 |
| PB Ratio | 12.9 |
| P/FCF Ratio | -8.81 |
| PEG Ratio | n/a |
Enterprise Valuation
Avadel Pharmaceuticals has an Enterprise Value (EV) of 1.14B.
| EV / Earnings | -7.09 |
| EV / Sales | 40.63 |
| EV / EBITDA | -7.62 |
| EV / EBIT | -8.24 |
| EV / FCF | -8.84 |
Financial Position
The company has a current ratio of 3.64, with a Debt / Equity ratio of 0.38.
| Current Ratio | 3.64 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.38 |
| Total Debt / Capitalization | 27.75 |
| Cash Flow / Debt | -3.81 |
| Interest Coverage | -13.94 |
Financial Efficiency
Return on equity (ROE) is -1.83% and return on capital (ROIC) is -111.61%.
| Return on Equity (ROE) | -1.83% |
| Return on Assets (ROA) | -0.97% |
| Return on Capital (ROIC) | -111.61% |
| Revenue Per Employee | 181.58K |
| Profits Per Employee | -1.04M |
| Employee Count | 154 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.08 |
Taxes
| Income Tax | -501.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -46.03% in the last 52 weeks. The beta is 1.63, so Avadel Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.63 |
| 52-Week Price Change | -46.03% |
| 50-Day Moving Average | 11.35 |
| 200-Day Moving Average | 14.37 |
| Relative Strength Index (RSI) | 28.57 |
| Average Volume (20 Days) | 1.40M |
Income Statement
In the last 12 months, Avadel Pharmaceuticals had revenue of 27.96M and earned -160.28M in profits. Earnings per share was -2.
| Revenue | 27.96M |
| Gross Profit | 27.12M |
| Operating Income | -137.85M |
| Net Income | -160.28M |
| EBITDA | -149.13M |
| EBIT | -137.85M |
| Earnings Per Share (EPS) | -2 |
Balance Sheet
The company has 31.17M in cash and 35.38M in debt, giving a net cash position of -4.22M.
| Cash & Cash Equivalents | 31.17M |
| Total Debt | 35.38M |
| Net Cash | -4.22M |
| Retained Earnings | -745.50M |
| Total Assets | 158.25M |
| Working Capital | 84.47M |
Cash Flow
In the last 12 months, operating cash flow was -128.51M and capital expenditures 0, giving a free cash flow of -128.51M.
| Operating Cash Flow | -128.51M |
| Capital Expenditures | 0 |
| Free Cash Flow | -128.51M |
| FCF Per Share | -1.6 |
Margins
Gross margin is 96.97%, with operating and profit margins of -492.97% and -573.17%.
| Gross Margin | 96.97% |
| Operating Margin | -492.97% |
| Pretax Margin | -574.96% |
| Profit Margin | -573.17% |
| EBITDA Margin | -533.29% |
| EBIT Margin | -492.97% |
| FCF Margin | -459.58% |
Dividends & Yields
AVDL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24.91% |
| FCF Yield | -16.62% |
Analyst Forecast
The average price target for AVDL is $20, which is 149.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 149.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 0.62 |
| Piotroski F-Score | 1 |